Pharmacy

Premier says leaders will be focused on improving productivity and reducing supply chain inefficiencies and pharmaceutical costs.

Rule may be pushed out to Oct. 1, to give new HHS appointees time to review regulations.

Marathon Pharmaceuticals' controversial $89,000-a-year drug spawned outrage, intense questioning from Congress; new price not yet disclosed.

Former FDA deputy director's connections are expected to be seen as conflicts of interest during confirmation process.

Blue Shield of California wants to create "a tiered pharmacy network" in its 2018 small- and large-group plans, according to preliminary proposals the company submitted to the California Department of Managed Health Care (DMHC), a state health insurance regulator.

Congressmen pitched a House bill that would expand the federal government's ability to negotiate drug prices, and they left feeling optimistic about what Trump will do.

In recent months, reports of five- and six-figure annual price tags for orphan drugs have amplified long-simmering concerns.

Closing a single factory could lead to shortages of hundreds of drugs.

Sharp growth in insured rate, aging population and chronic disease are major factors in spending, though stats suggest effort to control costs.

Emflaza treats a rare, devastating neuromuscular disorder, but patients have been importing the generic version of the drug from overseas for about $1,200 a year.